Search

Meeting Program

All times are in GMT-3, local time in Brazil.

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

Dec 13 2023

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical manifestations

The EHA Specialized Working Group (SWG) on Thrombocytopenias and Platelet Function Disorders and the EHA-SWG on Bleeding and Thrombosis are pleased to collaborate on a recent free webinar: "The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical…